Latest & greatest articles for buspirone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on buspirone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on buspirone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for buspirone

1. Role of maclobemide, buspirone, bethanechol, bupropion and cyproheptadine in treatment of sexual dysfunction

Role of maclobemide, buspirone, bethanechol, bupropion and cyproheptadine in treatment of sexual dysfunction Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

2. Buspirone Use in the Treatment of Atomoxetine-Induced Bruxism (PubMed)

Buspirone Use in the Treatment of Atomoxetine-Induced Bruxism 24206098 2014 07 16 2018 11 13 1557-8992 23 9 2013 Nov Journal of child and adolescent psychopharmacology J Child Adolesc Psychopharmacol Buspirone use in the treatment of atomoxetine-induced bruxism. 634-5 10.1089/cap.2013.0087 Yüce Murat M 1 Department of Child and Adolescent Psychiatry, Faculty of Medicine, Ondokuz Mayıs University , Samsun, Turkey . Karabekiroğlu Koray K Say Gökçe Nur GN Müjdeci Mahmut M Oran Meral M eng Case (...) Reports Letter 2013 11 09 United States J Child Adolesc Psychopharmacol 9105358 1044-5463 0 Adrenergic Uptake Inhibitors 0 Propylamines 0 Serotonin Receptor Agonists 57WVB6I2W0 Atomoxetine Hydrochloride TK65WKS8HL Buspirone IM Adrenergic Uptake Inhibitors adverse effects therapeutic use Atomoxetine Hydrochloride Attention Deficit Disorder with Hyperactivity drug therapy Bruxism chemically induced drug therapy Buspirone therapeutic use Child Follow-Up Studies Humans Male Propylamines adverse effects

Full Text available with Trip Pro

2013 Journal of Child and Adolescent Psychopharmacology

3. Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials. (PubMed)

Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials. An increasing number of abandoned clinical trials have forestalled efforts to advance the evidence base for the treatment of mood and anxiety disorders in children and adolescents. With this in mind, we sought to present and validate a Bayesian approach for the reanalysis of summary data in abandoned clinical trials and to review and re-evaluate available pharmacokinetic (...) , tolerability, and efficacy data from two large, randomized controlled trials of buspirone in pediatric patients with generalized anxiety disorder (GAD).Prospective, randomized, parallel-group controlled trials of buspirone in pediatric patients with GAD as well as associated pharmacokinetic studies were identified and data were extracted. In addition to descriptive statistics, marginal posterior densities for each variable of interest were determined and a Monte Carlo pseudosample was generated with random

2017 Journal of Child and Adolescent Psychopharmacology

4. Buspirone in the Management of Agitation and Aggression Associated With Dementia. (PubMed)

Buspirone in the Management of Agitation and Aggression Associated With Dementia. Buspirone, a nonbenzodiazepine anxiolytic, has been shown to decrease aggression in animal models and reduce agitation in a small number of patients with organic brain syndromes. An open pilot study was conducted to assess the usefulness of buspirone in managing agitation and aggression in elderly dementia patients. Sixteen patients, ages 65-89, with various types of dementia associated with severe agitation (...) and aggression were treated with buspirone. Outcome was measured by the Clinical Global Impression Scale. Significant improvement was noted in six patients. Buspirone holds promise as a modestly effective and relatively safe alternative to neuroleptics in the management of agitation and behavioral disturbances associated with dementia. More systematic trials are indicated.Copyright © 1993 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

2017 The American Journal of Geriatric Psychiatry

5. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. (PubMed)

Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. Cancer-related dyspnea is a common, distressing, and difficult-to-manage symptom in cancer patients, resulting in diminished quality of life and poor prognosis. Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea (...) in patients with COPD. The main objective of our study was to evaluate whether buspirone alleviates dyspnea in cancer patients.We report on a randomized, placebo-controlled trial of 432 patients (mean age 64, female 51%, lung cancer 62%) from 16 participating Community Clinical Oncology Program (CCOP) sites with grade 2 or higher dyspnea, as assessed by the Modified Medical Research Council Dyspnea Scale. Dyspnea was assessed by the Oxygen Cost Diagram (OCD; higher scores are better) and anxiety

Full Text available with Trip Pro

2015 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

6. Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01395953 Recruitment Status : Withdrawn (This study was withdrawn due to competing research interests

2011 Clinical Trials

7. [Efficacy of buspirone and fluoxetine in short-term treatment of bulimia nervosa]. (PubMed)

[Efficacy of buspirone and fluoxetine in short-term treatment of bulimia nervosa]. Bulimia nervosa (BN) is a common and disabling psychiatric disorder, which affects mainly young females. The basic therapeutic modalities include pharmacotherapy with selective serotonin reuptake inhibitors, cognitive behavioural therapy and combined treatment.This 12-week open label study was performed to assess the efficacy of buspirone-5-HT1A receptor agonist in the treatment of bulimia, and to compare (...) it with the efficacy of fluoxetine --the standard treatment of BN.We recruited 57 patients, who were assigned to two treatment groups-fluoxetine (n=35) and buspirone (n=22) At baseline, and after treatment we assessed the serotonin level in serum.At least 50% reduction in severity of bulimic symptoms was observed in 15/35 (42.9%) patients treated with fluoxetine and in 11/22 (50.0%) patients receiving buspirone. Depressive symptoms (Beck Depression Inventory) decreased significantly in both treatment groups (from

2006 Psychiatria polska

8. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. (PubMed)

An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. To examine the efficacy and safety of atomoxetine combined with buspirone versus atomoxetine monotherapy and placebo in adult attention-deficit/hyperactivity disorder (ADHD).In this randomized, 8-week, 3-arm, double-blind, placebo-controlled trial conducted from November 2004 through December 2005, 241 adults with ADHD were randomly assigned in a 2:2:1 ratio to receive up to twice (...) -daily atomoxetine and thrice-daily buspirone (n = 97), twice-daily atomoxetine (n = 97), or placebo (n = 47). Participants met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for ADHD. The primary efficacy measure was the adult ADHD Investigator Symptom Rating Scale (AISRS).Decrease in the AISRS total score was significantly greater for atomoxetine-buspirone than placebo at all time points from weeks 1 to 7, with an estimated mean difference of -4.80

2012 Journal of Clinical Psychiatry

9. Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. (PubMed)

Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. The authors report on a pilot double-blind comparison of buspirone with haloperidol in the treatment of agitation manifested by physical tension and motor activity in Alzheimer's disease (AD). A group of 26 nursing home residents underwent a 10-week comparison of 15 mg buspirone (n = 12) vs. 1.5 mg haloperidol (n = 14) per day. Tension and anxiety decreased to a greater extent (...) in those patients who were treated with buspirone. Although it is not possible to draw definitive conclusions from a treatment study that does not include a placebo group, these findings suggest the potential value of further clinical research on buspirone in managing agitation in AD.Copyright © 1996 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

2017 The American Journal of Geriatric Psychiatry

10. Effects of Buspirone on Agitation Associated With Dementia. (PubMed)

Effects of Buspirone on Agitation Associated With Dementia. Ten patients with probable Alzheimer's disease participated in an open-label study of buspirone for agitation. The starting dose of 15 mg/day was increased by 5 mg every week until maximal improvement or 60 mg/day was reached. A significant decrease in agitation scores occurred at an average dose of 35 mg/day.Copyright © 1993 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

2017 The American Journal of Geriatric Psychiatry

11. Double-blind, placebo-controlled, randomized phase I/IIa study (safety and efficacy) with buspirone/levodopa/carbidopa (SpinalonTM) in subjects with complete AIS A or motor-complete AIS B spinal cord injury. (PubMed)

Double-blind, placebo-controlled, randomized phase I/IIa study (safety and efficacy) with buspirone/levodopa/carbidopa (SpinalonTM) in subjects with complete AIS A or motor-complete AIS B spinal cord injury. No drug treatment capable of restoring locomotor capabilities in patients suffering a motor-complete spinal cord injury (SCI) has ever been developed. We assessed the safety and efficacy of an activator of spinal locomotor neurons in humans, which were shown in paraplegic animals to elicit (...) temporary episodes of involuntary walking.Single administration of buspirone/levodopa/carbidopa (SpinalonTM), levodopa/carbidopa (ratio 4: 1), and buspirone or placebo was performed using a dose-escalation design in 45 subjects placed in supine position who had had an SCI classified as complete (AIS A) or motor-complete/sensory incomplete (AIS B) for at least 3 months. Blood samples before and at regular intervals (15, 30, 60, 120, 240 min) after treatment were collected for hematological

2016 Current pharmaceutical design

12. Effects of acute buspirone administration on inhibitory control and sexual discounting in cocaine users. (PubMed)

Effects of acute buspirone administration on inhibitory control and sexual discounting in cocaine users. Cocaine users display deficits in inhibitory control and make impulsive choices that may increase risky behavior. Buspirone is an anxiolytic that activates dopaminergic and serotonergic systems and improves impulsive choice (i.e., reduces sexual risk-taking intent) in cocaine users when administered chronically. We evaluated the effects of acutely administered buspirone on inhibitory control (...) and impulsive choice.Eleven subjects with a recent history of cocaine use completed this within-subject, placebo-controlled study. Subjects performed two cued go/no-go and a sexual risk delay-discounting task following oral administration of buspirone (10 and 30 mg), triazolam (0.375 mg; positive control), and placebo (negative control). Physiological and psychomotor performance and subject-rated data were also collected.Buspirone failed to change inhibitory control or impulsive choice; however, slower

Full Text available with Trip Pro

2017 Human psychopharmacology

13. Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. (PubMed)

Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. Cognitive deficits are often associated with acute depressive episodes and contribute to the functional impairment seen in patients with Major Depressive Disorder (MDD). Many patients sustain residual cognitive deficits after treatment that may be independent of the core MDD disorder. We tracked changes in cognitive deficits relative to antidepressant treatment response using (...) the patient self-rated Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) during a 6-week, double-blind trial of a combination antidepressant treatment (buspirone 15 mg with melatonin-SR 3 mg) versus buspirone (15 mg) monotherapy versus placebo in MDD patients with acute depressive episodes. The CPFQ includes distinct cognitive and physical functioning dimension subscales. Treatment response was determined using the Inventory of Depressive Symptomatology (IDSc30

2015 Journal of psychiatric research

14. Buspirone

Buspirone Top results for buspirone - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for buspirone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

15. Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. (PubMed)

Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. To determine safety and efficacy of the 5HT1A serotonin partial agonist buspirone on core autism and associated features in children with autism spectrum disorder (ASD).Children 2-6 years of age with ASD (N = 166) were randomized to receive placebo or 2.5 or 5.0 mg of buspirone twice daily. The primary objective was to evaluate the effects of 24 weeks (...) of buspirone on the Autism Diagnostic Observation Schedule (ADOS) Composite Total Score. Secondary objectives included evaluating the effects of buspirone on social competence, repetitive behaviors, language, sensory dysfunction, and anxiety and to assess side effects. Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.There was no difference in the ADOS Composite Total Score between baseline and 24 weeks among

Full Text available with Trip Pro

2016 The Journal of pediatrics

16. A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia. (PubMed)

A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia. The purpose of this study was to test the hypothesis that the addition of buspirone, a partial agonist of 5HT1A receptor, to ongoing treatment with typical antipsychotics would improve the positive and negative symptoms in patients with chronic schizophrenia.In this study, 50 patients including 40 male and 10 female were (...) recruited with chronic schizophrenia who were inpatients at psychiatric teaching hospital or asylums, aged between 18 and 65 years (mean age = 47 ± 10.02). All patients were on the stable dose of typical antipsychotics for at least 1-month, and their acute symptoms were controlled. Patients were allocated in a random fashion: 25 patients to buspirone at 30 mg/day plus typical antipsychotic and 25 patients to placebo plus typical antipsychotic. The positive and negative syndrome scale (PANSS), Simpson

Full Text available with Trip Pro

2015 Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

17. Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder

Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02273154 Recruitment Status : Unknown Verified October 2014

2014 Clinical Trials

18. Buspirone, Stress, and Attentional Bias to Marijuana Cues

Buspirone, Stress, and Attentional Bias to Marijuana Cues Buspirone, Stress, and Attentional Bias to Marijuana Cues - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Buspirone, Stress, and Attentional Bias (...) of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone. Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias. Condition or disease Intervention/treatment Phase Cannabis Use Disorder Drug: Buspirone Drug: Placebo Phase 2 Detailed Description: For nearly 40 years marijuana has remained the most widely used illicit drug in the US, with more than 50% of first-time users

2014 Clinical Trials

19. Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT01821690 Recruitment Status : Recruiting First Posted : April 1

2013 Clinical Trials

20. An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT01850355 Recruitment

2013 Clinical Trials